Drugs / JKB-122
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT04371718 | Nov 2020 → Nov 2023 | autoimmune hepatitis | TaiwanJ Pharmaceuticals Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT04255069 | Jun 2020 → Jun 2023 | metabolic dysfunction-associated steatohepatitis | TaiwanJ Pharmaceuticals Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT02556372 | Apr 2016 → Jan 2019 | autoimmune hepatitis | TaiwanJ Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT02293941 | May 2014 → Aug 2017 | chronic hepatitis C virus infection | TaiwanJ Pharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04313205 Comparator | Aug → Dec 2020 | autoimmune hepatitis | TaiwanJ Pharmaceuticals Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JKB-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02293941 ↗ |
| Action | Inhibit | “JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form” NCT04313205 ↗ |
| Route | Oral | “5mg, oral, once daily” NCT02293941 ↗ |
| Target | TLR4 | “JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form” NCT04313205 ↗ |